OS Therapies grants John Ciccio 300,000 options

The option award vests monthly only if the director is serving on each applicable vesting date.

Available on EDGAR 10/30/2026 - 08:59 PM EDT Accepted by SEC EDGAR 10/30/2026 - 08:59 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OS Therapies Inc. director John Ciccio received options to purchase 300,000 common shares on October 22, 2026, at an exercise price of $1.25 per share. The options vest in 12 equal monthly installments, provided he is serving as a director on each applicable vesting date, and expire October 22, 2036.

Holdings listed for October 22, 2026, include 20,000 common shares held directly and 435,835 held indirectly through Mill River Partners LLC. Ciccio serves on the LLC’s board of managers and shares voting and investment power over those shares.

Insider Trade Summary

Grant/Award: 300,000 shares

Grant/Award 1 txn

Insider Ciccio John

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock options (right to buy) F2	300,000	$0.00	$0.00
Holding	Common Stock F1	--	--	--
Holding	Common Stock	--	--	--

Holdings After Transaction: Stock options (right to buy) — 300,000 contracts (Direct); Common Stock — 435,835 shares (Indirect, Mill River Partners LLC); Common Stock — 20,000 shares (Direct)

Footnotes (2)

1. F1. John Ciccio serves on the board of managers of Mill River Partners LLC and shares voting and investment power with respect to these shares.
2. F2. On October 22, 2026, the reporting person was granted options to purchase 300,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan. These options vest in 12 equal installments on each monthly anniversary of the date of grant, provided that the reporting person is serving as a director of the issuer on each applicable vesting date.

Key Figures

Option award: 300,000 options to purchase common shares Exercise price: $1.25 per share Vesting installments: 12 equal monthly installments +3 more

6 metrics

Option award 300,000 options to purchase common shares Granted October 22, 2026

Exercise price $1.25 per share Options granted October 22, 2026

Vesting installments 12 equal monthly installments Subject to continued service as a director on each applicable vesting date

Option expiration October 22, 2036 Options granted October 22, 2026

Direct common-stock holdings 20,000 shares Listed for October 22, 2026

Indirect common-stock holdings 435,835 shares Held through Mill River Partners LLC; listed for October 22, 2026

Key Terms

stock option award agreement, amended and restated 2023 incentive compensation plan, vest

3 terms

stock option award agreement financial

"pursuant to the terms and conditions of a stock option award agreement"

A stock option award agreement is a legal document that gives a person the right to buy a company’s shares at a fixed price later, with clear rules about when those rights become usable, how long they last, and any conditions for exercising them. For investors it matters because these agreements can increase the total shares outstanding and affect company costs and incentives—like a coupon that can turn into new stock, changing ownership and future stock supply.

amended and restated 2023 incentive compensation plan financial

"the issuer's amended and restated 2023 incentive compensation plan"

vest financial

"These options vest in 12 equal installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did OSTX director John Ciccio receive?

John Ciccio received options to purchase 300,000 common shares at an exercise price of $1.25 per share. The award was granted October 22, 2026, and vests in 12 equal monthly installments while he serves as a director on each applicable vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ciccio John

(Last) (First) (Middle)

C/O OS THERAPIES INCORPORATED

115 PULLMAN CROSSING ROAD, SUITE 103

(Street)

GRASONVILLE MARYLAND 21638

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OS Therapies Inc [ OSTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								435,835	I	Mill River Partners LLC(1)
Common Stock								20,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options (right to buy)	$1.25	10/22/2026		A		300,000		(2)	10/22/2036	Common Stock	300,000	$0	300,000	D

Explanation of Responses:

1. John Ciccio serves on the board of managers of Mill River Partners LLC and shares voting and investment power with respect to these shares.

2. On October 22, 2026, the reporting person was granted options to purchase 300,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan. These options vest in 12 equal installments on each monthly anniversary of the date of grant, provided that the reporting person is serving as a director of the issuer on each applicable vesting date.

	/s/ John Ciccio	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)